Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Convatec
Thumbnail
March 04, 2022

Medicare’s new devices

A handful of medtechs will benefit from new reimbursement pathways – but others have been denied the chance.

Thumbnail
September 20, 2019

The contrasting fortunes of Envista and Smiledirectclub

Two dental companies go public inside a week, with very different results.

Article image
Vantage logo
July 25, 2019

Livongo enters the medtech float hall of fame

The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.

Article image
Vantage logo
January 14, 2019

Led by Tandem, small-cap medtechs pump up the value in 2018

The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.

Article image
Vantage logo
October 15, 2018

Convatec has a poor third quarter for the second year running

An October curse returns to haunt Convatec, and this time it has spooked the CEO.

Article image
Vantage logo
January 10, 2018

Smaller medtechs soar in ’17 but could now be too expensive

Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.

Vantage logo
October 17, 2017

How do you solve a problem like Maria?

Vantage logo
June 21, 2017

Smith & Nephew innovates in wound care, but no trade sale in sight

Vantage logo
March 31, 2017

Snippet roundup: Novartis meets CAR-T filing deadline, Numab snares Ono

Vantage logo
March 17, 2017

Snippet roundup: Medica and Cell Medica are in the money, but Endo and Valeant feel the pain

Vantage logo
January 19, 2017

Medtechs flock to London as 2016 sees biggest IPO ever

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.